MaxCyte Signs Strategic
Platform License with TG Therapeutics to Advance its Autoimmune
Cell Therapeutics Programs
TG Therapeutics to use
MaxCyte's Flow Electroporation® technology and ExPERT™ platform to
support the development and commercialization of azer-cel, its
allogeneic CD19 CAR T cell therapy program, for the treatment of
autoimmune diseases
ROCKVILLE, MD, February 12,
2024 -
MaxCyte, Inc., (Nasdaq: MXCT; LSE:
MXCT), a leading, cell-engineering focused
company providing enabling platform technologies to advance the
discovery, development and commercialization of next-generation
cell-based therapeutics, today announced they are entering into a strategic platform license (SPL)
with
TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical
company focused on the acquisition, development and
commercialization of novel treatments for B-cell
diseases.
Under the terms of the agreement, TG
Therapeutics obtains non-exclusive research, clinical and
commercial rights to use MaxCyte's Flow Electroporation® technology
and ExPERT™ platform. In return, MaxCyte is entitled to receive
annual licensing fees and program-related revenue.
TG Therapeutics entered into an
agreement with Precision BioSciences, Inc. and acquired a worldwide
license to Precision's Azercabtagene Zapreleucel (azer-cel), an
investigational allogeneic or "off the shelf" CD19 CAR T cell
therapy program for autoimmune diseases and all other non-oncology
indications. TG received clearance by the U.S. Food and Drug
Administration (FDA) of an Investigational New Drug (IND)
application for azer-cel in progressive forms of multiple sclerosis
(MS) and is targeting commencement of a Phase 1 trial in
2025.
"By leveraging our commercially
validated cell-engineering platform and optimized T cell
manufacturing workflow, TG Therapeutics is advancing toward their
Phase 1 clinical trial for the application of azer-cel in
progressive forms of MS," said Maher Masoud, President and CEO of
MaxCyte. "Our technology has been integral to the
manufacturing of allogeneic T cell immunotherapies and was
efficiently transferred from Precision BioSciences when TG
Therapeutics obtained
global rights for azer-cel for
autoimmune diseases in January 2024. With our new partnership,
we will continue to support the development of azer-cel to expand
the application to autoimmune diseases."
MaxCyte's ExPERT™ instrument
portfolio is the next generation of leading, clinically and
commercially validated electroporation technology for complex and
scalable cell engineering. By delivering high transfection
efficiency and cell viability, seamless scalability and enhanced
functionality, the ExPERT™ platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics.
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 25 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been designed
to support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology platform, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more
at maxcyte.com and
follow us on X and LinkedIn.
About TG Therapeutics
TG Therapeutics is a fully
integrated, commercial stage, biopharmaceutical company focused on
the acquisition, development, and commercialization of novel
treatments for B-cell diseases. In addition to a research pipeline
including several investigational medicines, TG Therapeutics has
received approval from the U.S. Food and Drug Administration (FDA)
for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients
with relapsing forms of multiple sclerosis, including clinically
isolated syndrome, relapsing-remitting disease, and active
secondary progressive disease, as well as approval by the European
Commission (EC) and the Medicines and Healthcare Products
Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with
RMS who have active disease defined by clinical or imaging features
in Europe and the United Kingdom, respectively. For more
information, visit tgtherapeutics.com, and
follow us on
X (formerly Twitter)
and on LinkedIn.
MaxCyte Contacts:
US IR
Adviser
Gilmartin
Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media
Relations
Spectrum
Science
Jordan Vines
jvines@spectrumscience.com
+1 540-629-3137
Nominated Adviser and Joint
Corporate Broker
Panmure Liberum
Emma Earl / Freddy
Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR
Adviser
ICR
Healthcare
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@icrhealthcare.com
TG
Therapeutics Contact:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media
Relations
Email: media@tgtxinc.com
Telephone: +1 877-575-TGTX (8489), Option
6
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. All statements other than statements of historical facts
contained in this press release, including statements regarding our
future results of operations or financial condition, business
strategy and plans and objectives of management for future
operations, are forward-looking statements. These statements are
inherently uncertain, and investors are cautioned not to unduly
rely on these statements.
Risks and uncertainties related to
our business are described in greater detail in Item 1A of our
Annual Report on Form 10-K for the year ended December 31, 2023,
filed with the Securities and Exchange Commission ("SEC") on March
12, 2024, as well as in discussions of potential risks,
uncertainties, and other important factors in the other filings
that we make with the Securities and Exchange Commission from time
to time, including in our Form 10-Q for the quarter ended September
30, 2024, filed with the SEC on November 6, 2024. These documents
are available through the Investor Menu, Financials section, under
"SEC Filings" on the Investors page of our website
at http://investors.maxcyte.com.
Any forward-looking statements in this press release are based on
our current beliefs and opinions on the relevant subject based on
information available to us as of the date of such press release,
and you should not rely on forward-looking statements as
predictions of future events. We undertake no obligation to update
any forward-looking statements made in this press release to
reflect events or circumstances after the date of this press
release or to reflect new information or the occurrence of
unanticipated events, except as required by law.
